

Melissa D Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5557391/publications.pdf>

Version: 2024-02-01

98
papers

4,301
citations

147801

31
h-index

110387

64
g-index

100
all docs

100
docs citations

100
times ranked

5656
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of alcohol-based hand-rub disinfection on bacterial bioburden on stethoscopes in a real-world clinical setting. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 1029-1031.	1.8	1
2	Harvesting the low-hanging fruit? Comparative assessment of intravenous to oral route antimicrobial conversion policy implementation. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 954-958.	1.8	2
3	How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2022, 74, e23-e33.	5.8	1
4	Top Myths of Diagnosis and Management of Infectious Diseases in Hospital Medicine. <i>American Journal of Medicine</i> , 2022, 135, 828-835.	1.5	3
5	Reply to Day et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 1627-1628.	4.0	1
6	Effects of a Collaborative, Community Hospital Network for Antimicrobial Stewardship Program Implementation. <i>Clinical Infectious Diseases</i> , 2021, 73, 1656-1663.	5.8	13
7	Antifungals in Clinical Use and the Pipeline. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 341-371.	5.1	17
8	The host transcriptional response to Candidemia is dominated by neutrophil activation and heme biosynthesis and supports novel diagnostic approaches. <i>Genome Medicine</i> , 2021, 13, 108.	8.2	10
9	Inflammatory Protein Profiles in Plasma of Candidaemia Patients and the Contribution of Host Genetics to Their Variability. <i>Frontiers in Immunology</i> , 2021, 12, 662171.	4.8	6
10	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.9	75
11	106. Pandemic Pinch: The Impact of COVID Response on Antimicrobial Stewardship Program (ASP) Resource Allocation. <i>Open Forum Infectious Diseases</i> , 2021, 8, S167-S168.	0.9	1
12	Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020, 70, 30-39.	5.8	79
13	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 221-228.	3.0	6
14	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83
15	Alcohol Hand Rub Significantly Reduces Overall Bacterial Bioburden on Stethoscopes in a Real-World Clinical Setting. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s114-s115.	1.8	0
16	598. Correlation of International Classification of Diseases (ICD) codes to initial provider-selected antibiotic indications in hospitalized adult patients within the Duke Antimicrobial Stewardship Outreach Network (DASON). <i>Open Forum Infectious Diseases</i> , 2020, 7, S362-S362.	0.9	1
17	Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 228-233.	3.0	7
18	2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes. <i>Open Forum Infectious Diseases</i> , 2019, 6, S715-S715.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1297-1300.	1.8	35
20	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. <i>Journal of Infectious Diseases</i> , 2019, 220, 862-872.	4.0	17
21	1013. Electronic Assessment of Empiric Antibiotic Prescribing Using Diagnosis Codes. <i>Open Forum Infectious Diseases</i> , 2019, 6, S356-S356.	0.9	0
22	2885. A Host Transcriptional Signature for Accurate Diagnosis of Candidemia in the Hospital Setting. <i>Open Forum Infectious Diseases</i> , 2019, 6, S76-S76.	0.9	1
23	2089. Effect of the Duke Antimicrobial Stewardship Outreach Network (DASON): A Multi-Center Time Series Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S705-S706.	0.9	3
24	996. Impact of Penicillin Allergy Labels on Carbapenem Use in a Multi-Center Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S350-S350.	0.9	0
25	1044. Impact of Interdisciplinary Rounds on Antimicrobial Use at a Community Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S368-S368.	0.9	1
26	1006. Do Antibiotic Choices Made in the ED Influence Inpatient Therapy?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S354-S354.	0.9	1
27	Feasibility and Value of Developing a Regional Antibigram for Community Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 718-722.	1.8	13
28	262. Pediatric Antibiotic Use in the Duke Antimicrobial Stewardship Outreach Network. <i>Open Forum Infectious Diseases</i> , 2018, 5, S110-S110.	0.9	0
29	1629. Targeted Antimicrobial Use Admission Provides an Actionable Denominator for Antimicrobial Stewardship Programs Evaluating Inpatient Length of Therapy. <i>Open Forum Infectious Diseases</i> , 2018, 5, S42-S42.	0.9	0
30	1819. Antibiotic Prescribing Feedback: Description of Denominator Metrics to Standardize Prescribing Rates for Peer Comparison. <i>Open Forum Infectious Diseases</i> , 2018, 5, S516-S517.	0.9	0
31	855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals. <i>Open Forum Infectious Diseases</i> , 2018, 5, S18-S18.	0.9	2
32	The homozygous CX3CR1-M280 mutation impairs human monocyte survival. <i>JCI Insight</i> , 2018, 3, .	5.0	25
33	Benchmarking Antimicrobial Use in Emergency Departments among Community Hospitals in the Duke Antimicrobial Stewardship Outreach Network. <i>Open Forum Infectious Diseases</i> , 2017, 4, S248-S249.	0.9	1
34	QTc Prolongation in Patients Receiving Triazoles and Amiodarone. <i>Open Forum Infectious Diseases</i> , 2017, 4, S84-S84.	0.9	3
35	Dosing Voriconazole in Obese Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, S292-S293.	0.9	0
36	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. <i>PLoS ONE</i> , 2017, 12, e0180824.	2.5	24

#	ARTICLE	IF	CITATIONS
37	Impact of an Antimicrobial Stewardship Protocol on Appropriateness of Meropenem Use in a Community Hospital. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
38	Developing a Regional Antibigram for Community Hospitals. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
39	Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. <i>Cell Reports</i> , 2016, 17, 2572-2583.	6.4	66
40	Genetic Susceptibility to Fungal Infections: What is in the Genes?. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 81-91.	3.4	34
41	Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications. <i>Critical Care Nurse</i> , 2016, 36, 37-46.	1.0	3
42	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	3.0	15
43	CXCR1-mediated neutrophil degranulation and fungal killing promote <i>Candida</i> clearance and host survival. <i>Science Translational Medicine</i> , 2016, 8, 322ra10.	12.4	71
44	Harvesting the Low Hanging Fruit: A Benchmarking Tool for Implementation of Intravenous to Oral Antibiotic Switch Programs in 14 Southeastern Community Hospitals. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	0
45	Characterization of Redundant Spectrum Antibiotic Use in Community Hospitals: A Stewardship Opportunity. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	0
46	<i>Candida</i> Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2365-2373.	3.2	68
47	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against <i>Candida</i> infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 963-974.	2.9	69
48	Predictors of glycaemic control among HIV-positive veterans with diabetes. <i>International Journal of STD and AIDS</i> , 2015, 26, 262-267.	1.1	7
49	Collaborative Drug Therapy Management and Comprehensive Medication Management—2015. <i>Pharmacotherapy</i> , 2015, 35, e39-50.	2.6	137
50	Variability in Antimicrobial Use Among Community Hospitals in the Duke Antimicrobial Stewardship Outreach Network. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	0
51	Utilization of Systemic Antifungal Therapy Among Community Hospitals in the Duke Antimicrobial Stewardship Network. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	0
52	929Comparison of Echinocandin vs Amphotericin B Based Therapy for <i>Candida</i> Infective Endocarditis: An Observational Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, S268-S269.	0.9	0
53	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. <i>BMC Immunology</i> , 2014, 15, 55.	2.2	54
54	ImmunoChip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014, 5, 4675.	12.8	76

#	ARTICLE	IF	CITATIONS
55	Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology oncology patients: a retrospective cohort study. <i>Cancer Medicine</i> , 2014, 3, 667-673.	2.8	34
56	Autophagy is redundant for the host defense against systemic <i>Candida albicans</i> infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 711-722.	2.9	35
57	Antifungal Catheter Lock Therapy for the Management of a Persistent <i>Candida albicans</i> Bloodstream Infection in an Adult Receiving Hemodialysis. <i>Pharmacotherapy</i> , 2014, 34, e120-7.	2.6	17
58	Role of autophagy genetic variants for the risk of <i>Candida</i> infections. <i>Medical Mycology</i> , 2014, 52, 333-341.	0.7	17
59	Circulating galectin-3 in infections and non-infectious inflammatory diseases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1605-1610.	2.9	38
60	Functional genomics identifies type I interferon pathway as central for host defense against <i>Candida albicans</i> . <i>Nature Communications</i> , 2013, 4, 1342.	12.8	157
61	Increasing Echinocandin Resistance in <i>Candida glabrata</i> : Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations. <i>Clinical Infectious Diseases</i> , 2013, 56, 1724-1732.	5.8	638
62	Pharmacological Considerations in Human Immunodeficiency Virus-Infected Adults in the Intensive Care Unit. <i>Critical Care Nurse</i> , 2013, 33, 46-56.	1.0	4
63	CX3CR1-dependent renal macrophage survival promotes <i>Candida</i> control and host survival. <i>Journal of Clinical Investigation</i> , 2013, 123, 5035-5051.	8.2	190
64	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. <i>Journal of Infectious Diseases</i> , 2012, 205, 934-943.	4.0	116
65	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 502-510.	5.8	68
66	Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. <i>Pharmacotherapy</i> , 2012, 32, 890-901.	2.6	57
67	Evaluation of a digital microfluidic real-time PCR platform to detect DNA of <i>Candida albicans</i> in blood. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 2237-2245.	2.9	67
68	Human genetic susceptibility to <i>Candida</i> infections. <i>Medical Mycology</i> , 2012, 50, 785-794.	0.7	37
69	The impact of caspase-12 on susceptibility to candidemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 277-280.	2.9	14
70	Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. <i>Pharmacotherapy</i> , 2012, , n/a-n/a.	2.6	1
71	Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. <i>Journal of Infectious Diseases</i> , 2011, 204, 1138-1145.	4.0	80
72	Ertapenem for treatment of osteomyelitis: a case series. <i>BMC Research Notes</i> , 2011, 4, 478.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Combination Antifungal Therapy. , 2011, , 153-163.		0
74	Use of Antifungal Combination Therapy: Agents, Order, and Timing. Current Fungal Infection Reports, 2010, 4, 87-95.	2.6	76
75	Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients. AIDS Research and Treatment, 2010, 2010, 1-4.	0.7	13
76	Host Genomics and Bacterial Infections. , 2010, , 744-759.		0
77	Host Genomics and Bacterial Infections. , 2009, , 1347-1361.		0
78	Pharmacogenomics of systemic antifungal agents. Current Fungal Infection Reports, 2009, 3, 111-116.	2.6	1
79	Mortality and time to extubation in severe hospital-acquired pneumonia. American Journal of Infection Control, 2009, 37, 143-149.	2.3	9
80	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. New England Journal of Medicine, 2009, 361, 1760-1767.	27.0	671
81	Echinocandins for Prevention and Treatment of Invasive Fungal Infections. , 2009, , 219-242.		0
82	Current Options in Antifungal Pharmacotherapy. Pharmacotherapy, 2008, 28, 614-645.	2.6	68
83	Analysis of two- and three-year trends in antimicrobial resistance in intensive care units using unit-specific antibiograms. Scandinavian Journal of Infectious Diseases, 2008, 40, 672-674.	1.5	6
84	Quantification of 1,3-β-D-Glucan Levels in Children: Preliminary Data for Diagnostic Use of the β-D-Glucan Assay in a Pediatric Setting. Vaccine Journal, 2007, 14, 924-925.	3.1	98
85	A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. International Journal of STD and AIDS, 2007, 18, 851-855.	1.1	20
86	Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplantation, 2007, 40, 297-306.	2.4	31
87	Fungal infections of the bones and joints. Current Infectious Disease Reports, 2007, 3, 450-460.	3.0	9
88	Caspofungin for Invasive Candidiasis at a Tertiary Care Medical Center. American Journal of Medicine, 2006, 119, 993.e1-993.e6.	1.5	13
89	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
90	Pharmacotherapy for Human Immunodeficiency Virus-Associated Nephropathy. Pharmacotherapy, 2005, 25, 1761-1772.	2.6	4

#	ARTICLE	IF	CITATIONS
91	Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Opinion on Pharmacotherapy, 2005, 6, 2617-2632.	1.8	24
92	Combination Antifungal Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 693-715.	3.2	478
93	Caspofungin: first approved agent in a new class of antifungals. Expert Opinion on Pharmacotherapy, 2003, 4, 807-823.	1.8	68
94	A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. Journal of Antimicrobial Chemotherapy, 2003, 51, 453-457.	3.0	49
95	Steady-State Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Infected Patients with End-Stage Renal Disease Receiving Chronic Dialysis. Antimicrobial Agents and Chemotherapy, 2002, 46, 2387-2392.	3.2	26
96	Fungal infections of the bones and joints. Current Infectious Disease Reports, 2001, 3, 450-460.	3.0	18
97	Fungal Infections of the Bones and Joints. Current Infectious Disease Reports, 2001, 3, 450-460.	3.0	5
98	Real World Effectiveness of Antifungal Prophylaxis with Posaconazole as the Primary Agent in Patients with Hematological Malignancies. Mycoses, 0, , .	4.0	0